On 2-3, SABRE hold a PSF in-house training for Abbvie SCBU. The participants include RM/high potential DM, MKT and product managers. With the patent cliff in pharm industry, and China’s generic drugs equivalent evaluation, and the expectation of foreign pharm firms on China MKT, they all requires a tough strategy for “sales ROI increasing even with less resources”. This program is to seek out the answer of this strategy to find out the new growth opportunity. It develops from 2 Tas.
1) Inhalation: ROI increasing with less resources
2) Nephrology: Where is the new chances/customers after be listed into drug catalogue.